Search PubMed⌕ Search

Biomedical subjects

M Ichimura

Publications and source records attributed to M Ichimura.

At least 73 records · Page 4Linked to original sources
PubMed1988

Effect of Japanese kampo medicine on hypothalamic-pituitary-ovarian function in women with ovarian insufficiency.

Twenty-five women who suffering with either amenorrhea, anovulatory cycle or luteal phase dysfunction were treated with TJ-23 and TJ-106 (Japanese Kampo medicine) orally for 10 to 30 weeks. Blood was taken every two weeks prior to and during treatment and serum levels of LH, FSH, prolactin, E2, progesterone (P) and testosterone were assayed. Premarin test and LH-RH test were examined prior to and during treatment. Of 7 women who were suffering with amenorrhea TJ-23 treatment brought about menstruation in 4 women; 3 were ovulated and TJ-106 brought about menstruation in 3 women; 2 were ovulated. Of 4 women with anovulatory cycle TJ-23 or TJ-106 treatment brought about ovulation in 2 women. Of 10 women with luteal phase dysfunction TJ-23 treatment brought about normal midluteal P levels in 7 women; 4 among them were pregnant, and TJ-106 brought about normal P levels in 6 women; one of them was pregnant. Improvement of hypothalamic-pituitary function was suggested during treatment by Premarin test and LH-RH test. These evidences infer that TJ-23 and TJ-106 may exert their effect on hypothalamic-pituitary area and may activate ovarian function; however, direct effect on ovary and factors except endocrine mechanism may not be excluded.

Benzoates↗
PubMed1988

Infantile muscle glycogen storage disease: phosphoglucomutase deficiency with decreased muscle and serum carnitine levels.

We report a 5-month-old boy with recurrent vomiting, lethargy, and poor weight gain. He had profound metabolic acidosis and nonketotic dicarboxylic aciduria. The serum and muscle carnitine levels were significantly low (60% and 10% of the control means, respectively), suggesting that the patient had a systemic carnitine deficiency syndrome. The patient showed apparent clinical improvement on oral carnitine administration. A quadriceps muscle biopsy revealed a slight increase in intrafiber lipid droplets and mild accumulation of glycogen in the subsarcolemmal portion. An anaerobic glycolysis in vitro study showed a block after glucose-1-phosphate and before glucose-6-phosphate. Direct measurement of individual glycolytic enzymes in muscle of the patient demonstrated a marked decrease in phosphoglucomutase (PGM) activity (13% of the control mean). The specific defect of PGM activity in this patient suggests that the block in the anaerobic glycolytic pathway is the primary abnormality. PGM deficiency can be added as a newly recognized cause of secondary systemic carnitine deficiency syndromes.

Carnitine↗
PubMed1988

[Ovarian response and induction of ovulation with human menopausal gonadotropin of different ratio of FSH to LH content in women with ovarian insufficiency].

Human menopausal gonadotropin (hMG) with different ratios of FSH to LH content (FSH: LH = 1.2:1 (GNR 1.2), FSH:LH = 1.6:1 (GNR 1.6), FSH:LH = 3:1 (GNR 3) in biological activity, respectively) was used in this study to examine the effects of these hMGs on ovary, and subsequent follicular maturation and ovulation. In 5 women, 300 IU of hMG (GNR 1.2, GNR 1.6 and GNR 3) was injected in turns during different midfollicular phases of the cycle (day 5-day 9) and serum estradiol (E2) was measured at 0, 24 hrs, 48 hrs, 72 hrs after injection to assess ovarian response to different hMG. Serum E2 response at 24 hrs, 48 hrs, 72 hrs after injection of hMG compared to the preinjected E2 level were 2.2, 1.8, and 1.5 fold with GNR 1.2; 2.6, 2.4 and 1.9 fold with GNR 1.6; and 2.2, 2.4 and 2.3 fold with GNR 3, respectively. These hMGs were administered in turns to women who were suffering from amenorrhea (6 cases), anovulatory (8 cases) and luteal phase dysfunction (10 cases) for treatment of ovarian dysfunction. The mean doses of hMG per cycle required to induce ovulation were 1,125 IU with GNR 1.2, 1,050 IU with GNR 1.6 and 925 IU with GNR 3 in these 24 women. The success rates for ovulation with GNR 1.2, GNR 1.6 and GNR 3 were 70.8, 79.2 and 87.5%. The appearance rates for ovarian hyperstimulation syndrome (OHSS) with GNR 1.2, GNR 1.6, and GNR 3 were 4.2, 8.3 and 8.3%, respectively. These results infer that a different ratio of FSH to LH in hMG has an effect on follicular maturation and ovulation, and that the increase in the rate of ovulation and prevention of OHSS may accompany the regulating of this ratio, and that hMG with a higher FSH content (ratio of FSH to LH is more than three) should be studied further as a promising agent to use in inducing ovulation in women.

Estradiol↗